Sedef Hande AKTAŞ, Ozan YAZICI, Zeki ÜSTÜNER, Nurullah ZENGİN, Fikri İÇLİ, Halime Nalan AKGÜN1, Hakan AKBULUT

A new angiogenesis prognostic index with VEGFA, PlGF, and angiopoietin 1 predicts survival in patients with advanced gastric cancer

Background/aim: The role of angiogenic factors in gastric cancer is not clear. We aimed to assess the role of vascular endothelial growth factor A (VEGFA), angiopoietin 1 (Ang-1), and placental growth factor (PlGF) in the prognosis of patients with advanced gastric cancer. Materials and methods: Thirty consecutive patients treated with a modified DCF (docetaxel, cisplatin, and fluorouracil) regimen were included in the study. The plasma VEGFA, Ang-1, and PlGF levels of the patients before treatment and following two cycles of chemotherapy were measured and evaluated as prognostic factors. Results: Poor performance status and lower Ang-1 levels were correlated with poor overall survival (OS). No significant correlation between VEGFA or PlGF and OS was found. An angiogenesis prognostic index (API) based on the levels of VEGFA, Ang-1, and PlGF was found to be highly correlated with OS. Performance status and API were found as independent prognostic factors for OS. Furthermore, a decrease in VEGFA by 25% from the pretreatment level was also found as a prognostic factor for OS independent of response to DCF regimen. Conclusion: Our results support the use of the new API including VEGFA, Ang-1, and PlGF levels in patients with advanced gastric cancer as a predictor of survival.

PDF

___

1. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010; 60: 222-243.
2. Khokhar NZ, Jiang Y, Benson AB, Ajani JA, Mulcahy MF. Refining docetaxel-containing therapy for gastric cancer. Gastrointest Cancer Res 2011; 4: 96-105.
3. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997.
4. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011; 29: 868-874.
5. Akbulut H, Altuntas F, Akbulut KG, Ozturk G, Cindoruk M, Unal E, Icli F. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine 2002; 20: 184- 190.
6. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Bachelor TT, Sorensen AG. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6: 327-338.
7. Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM et al. VEGFA as a marker for outcome among advanced breast cancer patients receiving anti-VEGFA therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008; 14: 7871- 7877.
8. Al-Moundhri MS, Al-Shukaili A, Al-Nabhani M, Al-Bahrani B, Burney IA, Rizivi A, Ganguly SS. Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. World J Gastroenterol 2008; 14: 3879-3883.
9. Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, Herbsty RS, Johnson BE, Heymach JV. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009; 15: 3600-3609.
10. Di Fabio F, Pinto C, Bucca E, Giaquinta S, Fabricio AS, Mutri V, Michilin S, Rojas Llimpe FL, Funaioli C, Gion M et al. Predictive value of circulating VEGFA in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma treated with cetuximab in combination with cisplatin and docetaxel (Italian phase II DOCETUX Study). J Clin Oncol 2008; 26 (May 20 Suppl.): 15605.
11. Taylor AP, Leon E, Goldenberg DM. Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement. Brit J Cancer 2010; 103: 82-89.
12. Zhang L, Chen J, Ke Y, Mansel RE, Jiang WG. Expression of placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol 2005; 3: 68.
13. Wei SC, Liang JT, Tsao PN, Hsieh FJ, Yu SC, Wong JM. Preoperative serum placenta growth factor level is a prognostic biomarker in colorectal cancer. Dis Colon Rectum 2009; 52: 1630-1636.
14. Chen CN, Hsieh FJ, Cheng YM, Cheng WF, Su YN, Chang KJ, Lee PH. The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett 2004; 213: 73-82.
15. Brudno Y, Ennett-Shepard AB, Chen RR, Aizenberg M, Mooney DJ. Enhancing microvascular formation and vessel maturation through temporal control over multiple proangiogenic and pro-maturation factors. Biomaterials 2013; 34: 9201-9209.
16. Moon WS, Park HS, Yu KH, Jang KY, Kang MJ, Park H, Tarnawski AS. Expression of angiopoietin 1, 2 and their common receptor Tie2 in human gastric carcinoma: implication for angiogenesis. J Korean Med Sci 2006; 21: 272- 278.
17. Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett 2013; 328: 18-26.
18. Park DJ, Yoon C, Thomas N, Ku GY, Janjigian YY, Kelsen DP, Ilson DH, Goodman KA, Tang LH, Strong VE et al. Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers. Ann Surg Oncol 2014; 21: 1130-1137.
19. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 2000; 6: 3147- 3152.
20. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909.
21. Ajani JA. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction - evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer 2008; 113: 945-955.
22. Aktas SH, Akbulut H, Akgun N, Icli F. Low dose chemotherapeutic drugs without overt cytotoxic effects decrease the secretion of VEGFA by cultured human tumor cells: A tentative relationship between drug type and tumor cell type response. Cancer Biomark 2012; 12: 135-140.
23. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996; 77: 858-863.
24. Peng L, Zhan P, Zhou Y, Fang WJ, Zhao P, Zheng Y, Zu N. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a metaanalysis. Mol Biol Rep 2012; 39: 9473-9484.
25. Tsuchida R, Das B, Yeger H, Koren G, Shibuya M, Thorner PS, Baruchel S, Malkin D. Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGFA/Flt1 autocrine signaling. Oncogene 2008; 27: 3923-3934.
26. Riedel F, Gotte K, Goessler U, Sadick H, Hormann K. Targeting chemotherapy-induced VEGFA up-regulation by VEGFA antisense oligonucleotides in HNSCC cell lines. Anticancer Res 2004; 24: 2179-2183.
27. Poon RTP, Lau CPY, Cheung ST, Yu WC, Fan ST. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 2003; 63: 3121-3126.
28. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7: 575-583.
29. Kim KJ, Cho CS, Kim WU. Role of placenta growth factor in cancer and inflammation. Exp Mol Med 2012; 44: 10-19.
30. Ho MC, Chen CN, Lee H, Hsieh FJ, Shun CT, Chang CL, Lai YT, Lee PH. Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett 2007; 250: 237-249.
31. Yuan HT, Khankin EV, Karumanchi SA, Parikh SM. Angiopoietin 2 Is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 2009; 29: 2011-2022.
32. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277: 48-50.
33. Fagiani E, Lorentz P, Kopfstein L, Christofori G. Angiopoietin-1 and -2 exert antagonistic functions in tumor angiogenesis, yet both induce lymphangiogenesis. Cancer Res 2011; 71: 5717- 5727.
34. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG. The Tie2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005; 118: 771-780.
35. Thomas M, Augustin HG. The role of the angiopoietins in vascular morphogenesis. Angiogenesis 2009; 12: 125-137.
36. Anargyrou K, Terpos E, Vassilakopoulos TR, Pouli A, Sachanas S, Tzenou T, Masouridis S, Christoulas D, Angelopoulou MK, Dimitriadou EM et al. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. Hematologica 2008; 93: 451-454.
37. Tabata C, Hirayama N, Tabata R, Yasumitsu A, Yamada S, Murakami A, Iida S, Tamura K, Fukuoka K, Kuribayashi K et al. A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma. Eur Respir J 2010; 36: 1099-1105.
38. Rahbari NN, Schmidt T, Falk CS, Hinz U, Herber M, Bork U, Büchler MW, Weitz J, Koch M. Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer 2011; 11.